Roche History & Founding Timeline

Roche invested billions in the crenezumab anti-amyloid programme over more than a decade, including a landmark prevention trial in a Colombian kindred with genetic Alzheimer's, without the patient selection biomarker discipline or dose optimisation that might have improved the probability of clinical success. The failure—alongside similar failures from Eli Lilly, Biogen, and others before the eventual lecanemab approval—reflected an industry-wide overconfidence in the amyloid hypothesis at doses that were insufficient to achieve meaningful plaque reduction, representing a costly lesson in the importance of pharmacodynamic biomarker validation before committing to large efficacy trials.

Roche's failure to establish Tecentriq as a leading checkpoint inhibitor—despite entering the market with clinically competitive data and regulatory approvals across multiple indications—reflects strategic errors in clinical trial design, commercial execution, and combination development partnership that allowed Merck's Keytruda to establish an insurmountable first-mover advantage. The voluntary withdrawal of Tecentriq's first-line lung cancer monotherapy approval in 2023 was the most visible consequence of a series of programme decisions that cumulatively failed to capitalise on the scientific potential of the PD-L1 mechanism.

Roche's historical strength in biologics—large-molecule antibodies and proteins produced by living cells—led to a relative underinvestment in the oral small molecule oncology space where competitors like AstraZeneca (Tagrisso), AbbVie (Imbruvica), and Eli Lilly (Verzenio) built blockbuster franchises in EGFR-mutant lung cancer, BTK inhibition, and CDK4/6 inhibition respectively. Roche's small molecule pipeline has improved through acquisitions and internal investment, but the decade-long underweighting of this modality left significant commercial opportunities to competitors.